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Background: Selection of patients with congenital heart disease for surgical septation in biventricular repair or
surgical palliation in functionally single ventricles requires low pulmonary vascular resistance (PVR). Where there
is uncertainty, PVR can be assessed using hybrid cardiovascular magnetic resonance (CMR) and fluoroscopic
(X-Ray) guided cardiac catheterizations (XMR). CMR/XMR catheterization is a validated technique for accurate
assessment of pulmonary vascular resistance. However, data concerning its application in clinical practice is
lacking.
Methods: PVR assessments were performed in 167 studies in 149 congenital heart disease patients by CMR/XMR
catheterization. Data was collated on patient demographics, procedural data, complications and outcomes. Institutional
ethics approval was obtained.
Results: Median age was 3.6 years (6 days - 67 years) and weight 13.8 kg (2.3 -122 kg). One hundred and eight studies
were in biventricular circulations and 59 in functionally single ventricles. Median radiation dose was 0.72 mSv. A
baseline Qp:Qs ≤2.75 in biventricular circulations with left-to-right shunts predicted a PVR ≥6 WU.m2 with 100%
sensitivity and 48% specificity. Median follow up until death or last review was 4.2 years (4 days - 11 years).
Eighty-four patients had a surgical or catheter intervention based on CMR/XMR catheterization findings at a
median of 94 days after the study. This included successful biventricular repair at resting PVR values ≤6 WU.m2
and Fontan completion at ≤4 WU.m2.
Conclusion: PVR measured by CMR/XMR catheterization allows accurate stratification for intervention in
patients with congenital heart disease in both, biventricular and univentricular circulations.
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Pulmonary hypertension with elevated pulmonary vascu-
lar resistance (PVR) causes significant morbidity and mor-
tality in children [1]. It has important implications in
association with congenital heart disease where an
elevated PVR precludes surgery for single ventricle palli-
ation and septation for biventricular repair. Consequently,
accurate assessment of pulmonary vascular resistance is
crucial to inform clinical decision-making in congenital
heart disease and where invasive studies for direct meas-
urement of pressures are still recommended [2].
There are recognized sources of error with the Fick
and thermodilution techniques in assessment of PVR
particularly in the presence of intracardiac shunts,
impaired function and single ventricle circulations with
multiple sources of pulmonary blood flow [3-5]. Com-
bined CMR and X-ray (XMR) guided cardiac catheteri-
zations allow for simultaneous measurement of invasive
pressures and CMR derived anatomy, function and
quantification of flow [6-9]. Clinical validation studies
have shown that CMR/XMR catheterization is more ac-
curate than standard cardiac catheterization using the
Fick method for the assessment of PVR in pulmonary
hypertension and congenital heart disease, particularly
in patients receiving 100% oxygen and inhaled nitric
oxide (iNO) [3,8,10].
We present results of PVR assessment by CMR/XMR
catheterization, which includes analysis of indications,
results and outcomes. We hypothesize that accurate
PVR measurements in this way can be reliably applied in
clinical decision making for septation in biventricular re-




One hundred and forty nine pediatric and adult patients
with congenital heart disease and clinical suspicion of
raised PVR on clinical assessment or echocardiography
underwent 167 CMR/XMR cardiac catheterizations in our
institution between February 2002 and February 2012.
Ethical approval was obtained by St. Thomas' Hospital
Research Ethics Committee/South East London Research
Ethics Committee prior to commencement of the CMR/
XMR cardiac catheterization program. This study includes
16 patients from previously published data describing the
early initial clinical experience of this technique [8] and 24
patients from the validation study of PVR calculation
using CMR/XMR [3].
Technique
The techniques of CMR/XMR catheterization have
been previously described [3,8,10-12]. In our hybrid
laboratory we used a 1.5 T MR-scanner (Achieva,Philips, Best, Netherlands) and a Philips BV Pulsera
cardiac X-Ray unit. All procedures were performed
under general anesthesia with sevofluorane and intraven-
ous remifentanyl. A heparin bolus of 50 IU/Kg was
given with activated clotting time (ACT) monitoring
once vascular access was obtained. Patients underwent
either solely CMR guided catheterization or XMR
catheterization.
For XMR catheterization procedures, catheters were
positioned in the appropriate vessels and chambers
using guide-wires where necessary under X-Ray guid-
ance. Once right heart catheterization was completed,
CMR compatible catheters (Wedge catheter, Arrow,
Reading, PA, USA) were left in place in the pulmonary
artery for continuous hemodynamic pressure monitor-
ing and the patient was transferred to the CMR scanner
on the sliding table.
For CMR guided catheterization, following an initial
reference scan, an interactive sequence was used for de-
termining and saving reference planes for catheter
guidance. During passive catheter tracking, a 2D steady
state free precession (SSFP) sequence (Balanced- FFE,
TE 1.45 ms, TR 2.9 ms, matrix 128×128), with a
temporal resolution of 10–14 frames per second was
used in which the catheter tip is seen on filling the
angiographic balloon with 1 ml of carbon dioxide [8,9].
For these patients, catheter placement for right heart
catheterization was performed solely under CMR
guidance.
To obtain flow measurements in major vessels, through
plane velocities were measured by means of phase con-
trast gradient echo sequences perpendicular to the long
axis planes of the vessel with either breath-hold or free-
breathing flow-sensitive segmented k-space fast field echo
sequence (approximate echo time 3 ms, approximate
repetition time 5 ms, matrix 128×256, field of view 250–
350 mm, flip angle 15°, number of signal averages 3, retro-
spective gating, 40 acquired phases).
Pulmonary vascular resistance (PVR)
Invasive pressure and phase contrast flow were mea-
sured simultaneously and repeated under different
physiological conditions. Throughout, we aimed for
hemodynamic stability in the patient and normocarbia
(PaCO2 4-5kPa). Baseline measurements were made in
30% inspired oxygen. Patients undergoing reversibility
studies had repeat measurements 20 minutes after ad-
ministration of inhaled nitric oxide (iNO) at 20 ppm
and 100% inspired oxygen. Pressures where measured
with breatholds and flows were measured consistently
as either free-breathing or with breatholds. Where
breatholds were used, they were limited to no longer
than 15 seconds and normocarbia was maintained as
observed using the measured end-tidal CO2.
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  ¼ mean PA pressure mmHgð Þ mean LA pressure mmHgð Þ½ 
indexed PA flow L=min=m2ð ÞLeft atrial (LA) pressure was either measured directly or
obtained from a pulmonary capillary wedge pressure
(PCWP) accepting that PCWP only remains a reliable
measure of LA pressure at values <15 mmHg. Units were
expressed as Wood units (WU) indexed to body surface
area (WU.m2). Mean pulmonary artery (PA) pressure was
either measured in the main PA or branch PAs. Where
branch PA flows and pressures were used, we measured








Statistical analysis was performed using SPSS software
(version 18; Chicago, Ill). Normally distributed data are re-
ported as mean ± standard deviation and data with skewed
variables as median and range. Statistical differences were
assessed by paired t-test analysis. The receiver operatorTable 1 Primary structural cardiac lesions of the study popula















Branch pulmonary stenosis 9
Tetralogy of Fallot 7
Pulmonary atresia/intact ventricular septum 1
Absent PV 1
Left heart obstructive lesions
Aortic arch hypoplasia 1
85characteristic (ROC) curve of the baseline Qp:QS and
PVR at baseline was performed. Statistical significance
was set a priori at p <0.05.
Results
Patients
Median age was 3.6 years (6 days-67 years) and weight
13.8 kg (2.3 -122 kg). There was a wide range of underlying
diagnoses described in Table 1. Seventeen patients had an
associated diagnosis of trisomy 21. Ninety-seven patients
had previous surgical or catheter interventions. Fifteen had
a single repeat CMR/XMR study, and 3 patients had 2 re-
peat CMR/XMR studies. One hundred and fifty four were
combined XMR catheterizations and 13 were solely CMR
guided cardiac catheterizations. Median radiation dose for
CMR/XMR catheterization was 3.6 Gycm2 (0.72 mSv)
(range 0–57.5 Gycm2), with a median screening time of
11.2 minutes (range 0–58.2 minutes). There were 2 proced-
ural complications; pulmonary hemorrhage and pulmonary
embolism with good recovery and no procedural deaths.tion
Univentricular N = 50
Unbalanced AVSD 6














Pentalogy of Cantrell 1
ccTGA 2
12
Figure 1 PVR in patients with biventricular circulations and left to right shunts undergoing interventions post CMR/XMR catheterization.
Patient death is marked in black.
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moved abroad. Follow up until death or last medical re-
view was available for the remaining patients over a me-
dian of 4.2 years (4 days to 11 years). The 4-day duration
was related to a death from extracardiac complaints ex-
plained later in the manuscript. Eighty-four studies led to
a cardiac intervention (catheter or surgical) at a median
interval of 94 days (0–414 days). The remaining patients
either had medical or conservative treatment.Pulmonary vascular resistance and clinical outcomes
Pulmonary vascular resistance results are reported separ-
ately for biventricular and functionally single ventricle
circulations.Biventricular circulations
One hundred and eight PVR studies were performed in
biventricular circulations. Forty-seven led to a cardiac
intervention and 61 followed a conservative path or non-
cardiac intervention. Median PVR was 2.8 WU.m2 (range
0.4-66.0). Sixty-seven studies were in a group with lesions
that allowed shunting between the systemic and pulmon-
ary circulations or potentially vice-versa. Of these, 41 went
on to have a cardiac catheter or surgical intervention to
eliminate or substantially reduce the shunt. The PVR
values of this interventional group of patients are dis-
played in Figure 1. ROC analysis showed that a baseline
Qp:Qs ≤2.75 in biventricular circulations with left-to-right
shunts predicted a PVR ≥6 WU.m2 with 100% sensitivity
and 48% specificity (Figure 2 and Figure 3). This translates
to a negative predictive value of 100% and a positive pre-
dictive value of 37%.Reversibility with 20 ppm iNO and 100% oxygen were
performed in 52 studies with systemic to pulmonary
shunts, with a fall in mean PVR from 3.3 to 2.9 WU.m2
(p = 0.03) and a rise in mean Qp:Qs ratio from 2.2 to 2.4
(p = 0.02). Further interrogation showed a mean reduc-
tion of PVR by 12.7% (range 0-38%) in those undergoing
interventions and 10.8%(range 0-34%) in those who were
managed medically (p = 0.4).
A baseline PVR of around 6 WU.m2 and lower was
considered suitable for biventricular surgical repair,
accepting the need for fenestrated closure of left-to-right
(L-R) shunt lesions in the borderline cases. Those with a
PVR < 6 WU.m2 remain alive post intervention with only
one death, unrelated to PVR (PVR of 2 WU.m2) in a pa-
tient with pulmonary atresia, ventricular septal defect
and major aortopulmonary collaterals who required
multiple surgical and catheter interventions to address
residual proximal branch PA narrowing. This low PVR
group included four adult patients with chronic L-R
shunts (AVSDs or VSD) who went on to have surgery at
a mean age of 46 years (range 35.6-52.8 yrs) and remain
alive with no evidence of pulmonary hypertension.
Six patients with biventricular circulations had a
fenestrated, rather than complete closure of their intra-
cardiac shunt lesions due to the marginally elevated
PVR, three of whom had a PVR just above 6 WU.m2
(6.2, 6.3 and 6.7 WU.m2). Of these, one patient died
following surgical intervention despite fenestrated clo-
sure, from persistent pulmonary hypertension. This pa-
tient had an elevated pre-surgical PVR of 6.2 WU.m2
falling to 4.8 WU.m2 in response to maximum pulmo-
nary vasodilation during the PVR study and a Qp:Qs
that remained static at 1.1.
Figure 2 Relationship of PVR to Qp:Qs in biventricular circulations with aorta-to-pulmonary shunts.
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lesions who were not operated, 11 were because of an
elevated PVR of >6 WU.m2 (median 15 WU.m2 range
6.6-66 WU.m2) and remain alive on medical treatment.
The remaining 15 patients with PVR <6 WU.m2 (median
2.4 WU.m2, range 0.6-5.3 WU.m2) were managedFigure 3 ROC curve for the relationship of PVR to Qp:Qs in biventricu
the curve is 0.829.conservatively as the defects were judged to be small. There
was one death in this low PVR group in a patient with a
ventricular septal defect, VACTERL association (Vertebral
anomalies, Anal atresia, Cardiac defects, Tracheo-
oesophageal fistula and or Eosophageal atresia, Renal and
radial anomalies and Limb defects) and chronic lunglar circulations with aorta-to-pulmonary shunts. The area under
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difficulties.
Forty one patients had a biventricular circulation with-
out a lesion that allowed shunting between the systemic
and pulmonary circulations or potentially vice-versa
(median PVR 3.1 WU.m2 (0.6-31.4 WU.m2). Four pa-
tients with low PVR went on to have catheter or surgical
intervention with 3 stenting of the right ventricular out-
flow tract or branch pulmonary arteries, and one balloon
of the pulmonary valve. Two patients with a PVR greater
than 6 WU.m2 (19 and 6.2 WU.m2) underwent catheter-
guided occlusion of aortopulmonary collaterals. The pa-
tient with a PVR of 19 WU.m2 had a previously repaired
hypoplastic aortic arch and died from pulmonary hyper-
tension despite embolization of a right MAPCA and ini-
tiation of sildenafil. The second patient with Scimitar
syndrome survived.
Of the remaining patients without shunt lesions, eight had
no cardiac interventions but underwent a liver transplant
with good outcomes. The remaining 27 patients have had
no interventions and remain alive at last follow up. Eleven
had normal PVR and were managed conservatively (median
PVR 1.8 WU.m2, range 1.0-3.4) and 16 were treated with
oral pulmonary vasodilators for varying periods of time (me-
dian PVR 8.0, range 2.0-42.3 WU.m2).
Functionally univentricular circulations
Standard care for the preoperative assessment of patients
undergoing single ventricle surgical palliation at our cen-
ter has not involved cardiac catheterization since 2002.
Patients progressing along the path of surgical single ven-
tricle palliation undergo a CMR with simultaneous meas-
urement of central venous pressure by means of jugular
venous cannulation. Fifty-nine catheter studies wereFigure 4 PVR in patients with univentricular circulations undergoing
catheterization. Patient deaths are marked in black.performed in 50 patients with functionally univentricular
circulations where there were concerns regarding an ele-
vated PVR. Thirty-seven studies led to a cardiac interven-
tion, and 22 followed a conservative course. Median PVR
was 2.3 WU.m2 (range 0.9-6.6 WU.m2).
Forty-two studies were performed in 35 patients prior
to completion of Hemifontan or Fontan. Twenty patients
went on to have completion of the Fontan circulation
(Figure 4) despite a raised PVR in 4 patients (PVR 4.6, 3.9,
3.3 and 3.1 WU.m2). The median pulmonary artery pres-
sure pre-Fontan was 10.4 mmHg (range 6-18 mmHg). It
is our institutional practice to routinely fenestrate all
Fontans. There was one long-term death in a patient with
a PVR of 4.6 WU.m2, reducing to 3.6 WU.m2 with iNO
and 100% oxygen undergoing a high risk Fontan on silden-
afil therapy. There was one death (PVR 1.8 WU.m2) due to
plastic bronchitis 85 days post completion of Fontan.
Of the 15 patients who did not have Fontan comple-
tion, 3 had a PVR > 4 WU.m2 and were medically treated
for pulmonary hypertension, with one death. Of patients
managed conservatively with a PVR < 4 WU.m2, one is
awaiting surgery for completion of Fontan upon reduc-
tion of body mass index, and two were deemed unsuit-
able for Fontan completion despite a PVR <4 WU.m2
due to primary ciliary dyskinesia/cystic fibrosis in one,
and branch pulmonary arteries that were considered too
small in the other. Six patients remain palliated with
cavopulmonary shunts and have not been referred for
pre-Fontan assessment as yet. Three patients died pre
Fontan from complications unrelated to PVR. The first
patient died following surgery for unrelated endocarditis
of the mitral valve. The second patient had a sudden
arrhythmic death. The third patient was a neonatal death
following withdrawal of care 40 days after a redo ofstaged surgical palliation to completion of Fontan post CMR/XMR
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multiple congenital anomalies and associated complica-
tions from necrotising enterocolitis.
Fifteen patients had 17 studies post-Fontan completion
(median 2.1 WU.m2, range 0.9-4.3 WU.m2) of whom 12
were treated conservatively or with medical therapy. The
remaining 3 led to catheter interventions, which con-
sisted of coil occlusion of aortopulmonary collaterals
(PVR 2.2 WU.m2), lateral tunnel fenestration creation
and stenting (PVR 2.9 WU.m2) and fenestration closure
(PVR 1.4 WU.m2). All remain alive.
Discussion
In this study, we report CMR/XMR derived PVR values
and long-term outcomes over a median of 4.2 years in a
large cohort of patients with biventricular and single
ventricle physiology. This provides a basis for accurate
stratification of patients with congenital heart disease
being considered for interventions.
Pulmonary vascular resistance
Our data demonstrates that patients with significant L-R
shunt lesions with PVR values of up to 6 WU.m2 were
shown to have good long-term outcomes following surgical
repair even if this was carried out well into adulthood.
There was however a need for fenestrated closure in those
with moderately raised PVR. The commonly accepted cri-
teria for intervention in patients with moderately raised
PVR is based on consensus opinion [13] and suggests that
patients with intracardiac shunts are suitable for surgical
biventricular repair if the resting PVR is less than 6 WU.m2.
However, long-term outcome data using accurate PVR as-
sessment techniques in congenital heart disease are lack-
ing. Careful selection of patients is important as closure of
atrial septal defects in patients with elevated pulmonary
artery pressures without PVR assessment has resulted in
poor outcomes [14].
As the thresholds for interventions are stretched, it is
important to remember that pulmonary hypertension oc-
curring in the postoperative patient with congenital heart
disease carries a 23% mortality which is far worse [15]
than in unoperated patients who develop Eisenmenger
syndrome. Therefore, careful selection of appropriate pa-
tients is crucial to avoid prematurely lowering life expect-
ancy. Our data provides objective support for the use of
the current threshold for intervention of 6 WU.m2. One
out of 3 patients with a PVR > 6 WU.m2 died from pul-
monary hypertension having had an intervention in com-
parison to the 11 patients in the same PVR group who all
remain alive without any medical or catheter intervention.
Careful selection of patients using detailed PVR assess-
ment has allowed us to successfully perform late repair of
VSDs in adults who may have otherwise been deemed too
high risk. This is in keeping with previous reports [16].Defining PVR thresholds is also vital for patients being
put forward for single ventricle surgical palliation where
a lower PVR is crucial for adequate pulmonary blood
flow in the absence of a subpulmonary ventricle. In our
experience, single ventricle palliation was shown to re-
sult in favorable outcomes in patients with a PVR of less
than 4 WU.m2. The one patient in our cohort with a
PVR >4 WU.m2 who underwent single ventricle palli-
ation did not survive. This is in keeping with the original
‘10 commandments’ as described by Choussat which in-
clude a PVR <4 WU.m2 and mean pulmonary artery
pressures <15 mmHg. Many of these commandments
have been dispensed with over the years, but Hosein
et al. [17] have demonstrated increased adverse out-
comes post Fontan in the presence of pre surgical ele-
vated mean pulmonary artery pressures >16 mmHg and
impaired systolic ventricular function. Hosein et al. how-
ever noted the difficulty in assessing PVR accurately in
these patients and were not able to correlate this to out-
comes, both of which we have been able to achieve with
CMR/XMR guided catheterization even were there were
multiple sources of pulmonary blood flow. We have also
demonstrated good outcomes following Fontan comple-
tion with mean PA pressures of up to 18 mmHg where
the measured PVR was in fact low, though caution must
be exercised in interpretation of these data given the
small number of patients.
Pulmonary vascular resistance reversibility
There is no fixed guideline for the degree of reversibility
in PVR in response to pulmonary vasodilators as a
threshold for a positive response in pediatric patients
with congenital heart disease. However, consensus sug-
gests a reduction in PVR of 20% as a positive response
[13]. We found that no significant differences in the de-
gree of reduction of PVR in response to pulmonary va-
sodilators in those undergoing interventions compared
to those managed medically. In our population, the
underlying value of the baseline PVR was probably more
meaningful than response to pulmonary vasodilators in
terms of the decision to intervene with good long-term
outcomes.
Non-invasive assessment of PVR
Patients with unrestricted left to right shunts can have
PVR assessed non-invasively as we have previously out-
lined [18] in a study of 26 of these patients. We previ-
ously observed that a Qp:Qs of ≤2.5:1 predicted a PVR
of ≥3.5 WU.m2 with sensitivity 100%, and specificity
83%. We have expanded this to include more datasets
and refined this value such that a baseline Qp:Qs ≤2.75
in biventricular circulations predicted a PVR ≥ 6 WU.m2
with 100% sensitivity and 48% specificity. Therefore in
biventricular circulation with left to right shunts, it
Pushparajah et al. Journal of Cardiovascular Magnetic Resonance  (2015) 17:28 Page 8 of 9would be possible to avoid cardiac catheterization if the
Qp:Qs can be measured accurately and is greater than
2.75. However a lower Qp:Qs is not sufficiently predict-
ive of a high PVR and these patient should still undergo
assessment by cardiac catheterization. Importantly, a
Qp:Qs ≤2.75 in a patient with a small, restrictive PDA,
VSD, or ASD is not necessarily indicative of elevated pul-
monary vascular resistance. For instance, a high Doppler
peak velocity in a small PDA or VSD in conjunction with
normal systolic interventricular septal configuration on
two-dimensional echocardiography provides presumptive
evidence of normal pulmonary vascular resistance.
Radiation exposure
Solely CMR guided catheterization is possible [6,8,10] but
is limited in congenital heart disease where catheter ma-
nipulation is often performed with the aid of non-CMR
compatible guidewires under X-ray guidance due to the
complex anatomy. The variation in our practice for using
solely guided CMR compared to XMR was related in part
to anatomical constraints and the experience of the oper-
ator. Despite the need for X-ray fluoroscopy, the radiation
doses in CMR/XMR catheterization remain low. The me-
dian radiation exposure of 0.72 mSv compares favorably
against conventional fluoroscopic diagnostic catheterization
in contemporary literature of 10.8 mSv [19]. The role for
solely CMR guided catheterisation will expand in line with
developments in CMR compatible catheters and guide
wires where there are developments from a number of
companies with CE marking achieved or imminent.
Applicability
The need for accurate assessment of PVR is more pressing
given the complexity of patients undergoing treatment due
to improved surgical and interventional outcomes for con-
genital heart disease. CMR/XMR catheterization is a useful
clinical tool for accurate PVR assessment, but requires spe-
cialist hardware and a skilled multidisciplinary team.
Where there are cost implications for hybrid XMR suites,
XMR catheterization could still be performed as a single
procedure in separate laboratories provided there is close
proximity between the catheter laboratory and CMR scan-
ner and that patient safety is not compromised. Finally,
performing cardiac catheterisation in patients with elevated
PVR can be challenging and there are reports of occasional
mortality. Therefore, appropriate pre-procedure assess-
ment with skilled anaesthetic support must take place.
Limitations
All patients referred for CMR/XMR evaluation had a
high suspicion of abnormal hemodynamics requiring
more thorough evaluation and therefore represent a se-
lected population. It should be stressed that it is our in-
stitutional practice to base surgical decision-making forthese patients on clinical findings, echocardiography and
CMR data without routine diagnostic catheterization
[7,8,12,20,21] in keeping with the contemporary con-
genital heart practice of others. This highlights the
targeted role of CMR/XMR evaluation of PVR.
It is our institutional practice to perform all cardiac
catheter procedures under general anesthesia with 30%
fraction of inspired oxygen, which may affect PVR. Also
due to potential effects of positive pressure ventilation in
single ventricle patients we are careful to eliminate posi-
tive end expiratory pressure particularly in this group
when pressure measurements are being done.
Conclusion
CMR/XMR catheterization is safe and accurate tool in
the measurement of PVR and allows risk stratification of
patients with congenital heart disease being considered
for interventions. We have identified discrete PVR
thresholds below which good long-term outcome can be
achieved following surgical repair or palliation.
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